PER 1.37% 7.2¢ percheron therapeutics limited

Ann: Company Appointment Chief Commercial Officer, page-61

  1. 835 Posts.
    lightbulb Created with Sketch. 745
    I am not sure what you mean by "wasting EMA trial acceptance"

    Long COVID, i thought this was reported about 7 weeks ago?
    "One of the aims of the proteomics analysis was to assess if Neuro Long COVID-19 patients may have been amendable to treatment with ANP’s immunomodulatory drug ATL1102 which has previously demonstrated biologic activity in MS patients11 and the ability to reduce T cells and modulate proteins involved in the blood of DMD patients (data presented at the 2021 World Muscle Society conference WMS-ATL1102-DMDPROTEOMICS-Poster). Encouragingly, one of the potential therapeutic markers in Long COVID-19 patients identified from this proteomics analysis is also known as having the potential to be significantly modulated by ATL1102 in DMD patients and therefore is suggestive of its therapeutic potential in Long COVID-19. The Company is looking to further explore the clinical potential of ATL1102 in this setting via applying for grant funding opportunities (such as that as offered by NIH) in collaboration with Professor Koralnik. Dr Koralnik said, “The collaboration with Antisense Therapeutics has generated promising novel data in Long COVID-19 patients in identifying potential disease biomarkers and represents an important advance towards the goal of establishing effective disease diagnostics and interventional treatments. We look forward to continuing our scientific collaboration with Antisense Therapeutics and to advancing such endeavors through our active involvement and support in seeking grant applications including with bodies such as the NIH.” Dr George Tachas Director of Drug Discovery at Antisense Therapeutics said, “We are delighted to report on the initial outcomes from this novel and leading scientific collaboration with Professor Koralnik and his team. Our data has identified potential new avenues towards diagnoses and treatment of a disease that has negatively impacted the lives of over a hundred million people around the world. We look forward to continuing scientific advancements in the space in collaboration with Professor Koralnik and the further important IP that we anticipate emerging from this important scientific collaboration.” For further details please refer to the presentation following this announcement. "

    I thought people had responded to your query previously re "production in USA of ATL1102 that was ready to be packed and shipped"?

    Yes Imp, Google is your friend.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
-0.001(1.37%)
Mkt cap ! $64.91M
Open High Low Value Volume
7.4¢ 7.5¢ 7.2¢ $66.67K 916.5K

Buyers (Bids)

No. Vol. Price($)
3 127509 7.2¢
 

Sellers (Offers)

Price($) Vol. No.
7.4¢ 97444 1
View Market Depth
Last trade - 15.23pm 24/05/2024 (20 minute delay) ?
Last
7.2¢
  Change
-0.001 ( 2.70 %)
Open High Low Volume
7.3¢ 7.3¢ 7.2¢ 1650
Last updated 13.54pm 24/05/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.